Patents by Inventor Toshio Yoshizawa

Toshio Yoshizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10409196
    Abstract: An image forming apparatus includes an intermediate transferor to rotate in a predetermined rotation direction, a plurality of image bearers disposed along the intermediate transferor to bear latent images, a plurality of developing devices to develop the latent images, a plurality of developer containers to contain developers, and a plurality of conveyance paths each corresponding to a respective one of the plurality of developing devices and a respective one of the plurality of developer containers to supply the developers to the plurality of developing devices respectively. An arrangement of the plurality of developing devices in the predetermined rotation direction is configured to be changed without changing an arrangement of the plurality of developer containers. A layout of the plurality of conveyance paths is configured to be changed without changing connections between a supply source and a supply destination of the plurality of conveyance paths.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: September 10, 2019
    Assignee: RICOH COMPANY, LTD.
    Inventors: Toshio Koike, Jun Shiori, Teppei Kikuchi, Michiharu Suzuki, Kazuhiro Aso, Keinosuke Kondoh, Tadashi Ogawa, Hideo Yoshizawa
  • Patent number: 10370377
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 6, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20190227479
    Abstract: An image forming apparatus includes an apparatus body, a removable component configured to be removably installed in an installation position in the apparatus body, a cover configured to open and close when the removable component is removed from or installed in the installation position, a replacement removable component configured to be installable in and removable from the installation position in which the removable component is installed, and a holder configured to hold the replacement removable component at a different position from the installation position when the removable component is installed in the installation position and the cover opens. The replacement removable component held by the holder is configured to inhibit the cover from closing.
    Type: Application
    Filed: January 3, 2019
    Publication date: July 25, 2019
    Applicant: RICOH COMPANY, LTD.
    Inventors: Michiharu SUZUKI, Jun SHIORI, Hideo YOSHIZAWA, Toshio KOIKE, Teppei KIKUCHI, Kazuhiro ASO, Keinosuke KONDOH
  • Publication number: 20190219951
    Abstract: A developing device includes a developer bearer opposed to an image bearer, configured to bear developer and rotate in a direction of rotation of the developer bearer, and configured to develop a latent image on the image bearer and a casing opposed to the developer bearer at a position downstream from an opposed position, at which the developer bearer is opposed to the image bearer, in the direction of rotation of the developer bearer. A casing gap between the developer bearer and the casing continuously decreases or increases from a first end of the developing device to a second end of the developing device across a center of the developing device in a longitudinal direction of the developing device.
    Type: Application
    Filed: December 5, 2018
    Publication date: July 18, 2019
    Inventors: Toshio KOIKE, Jun Shiori, Hideo Yoshizawa, Keinosuke Kondoh, Teppei Kikuchi, Kazuhiro Aso, Michiharu Suzuki
  • Publication number: 20190169192
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 10296131
    Abstract: A monitoring and controlling apparatus includes a functional cabinet, functional units, and a control cabinet. The functional cabinet includes a plurality of frames and a door at an opening of at least a part of the frames, each frame having a predetermined accommodation size. Each functional unit is detachably accommodated in respective frame and including a circuit and a component for a function of the functional unit. The control cabinet is disposed next to the functional cabinet, and configured to monitor and control the functional units.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 21, 2019
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Atsuo Haryu, Akimasa Nakai, Shinji Sakurai, Susumu Yoshizawa, Katsuya Kasai, Kenichi Hosoya, Eiji Watanabe, Yusuke Tsuboi, Kazuaki Omomo, Toshio Tagawa
  • Patent number: 10233185
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 19, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20190054090
    Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 21, 2019
    Inventors: Sriram Venkataraman, Daniel B. Tumas, Kohei Tanaka, Tomoko Yasuhiro, Toshio Yoshizawa
  • Publication number: 20190054091
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 21, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio YOSHIZAWA, Ryohei KOZAKI
  • Publication number: 20180353512
    Abstract: Provided herein are methods that relate to a therapeutic strategy for treatment of a B-cell malignancy. In particular, the methods include administration of a PI3K inhibitor and a BTK inhibitor.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 13, 2018
    Inventors: Helen Collins, Julie Di Paolo, Kathy Keegan, Ryohei Kozaki, Sarah Meadows, Cara Nelson, Christophe Queva, Srinivasan Ramanathan, Stacey Tannheimer, Daniel Tumas, Tomoko Yasuhiro, Toshio Yoshizawa
  • Patent number: 10137129
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: November 27, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio Yoshizawa, Ryohei Kozaki
  • Publication number: 20180244675
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Publication number: 20180170933
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 9981966
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 29, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9926322
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 27, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9896453
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 20, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9879013
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 30, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20170313705
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 2, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Publication number: 20170313706
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 2, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 9732082
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 15, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa